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Purpose or Objective  
Diffusion-weighted MR imaging (DWI), used to measure 
apparent diffusion coefficient (ADC), provides biological 
information related to tumor cellularity and integrity of 
cell membranes and it is sensitive to intratumoral 
changes induced by chemoradiation therapy (CRT). 
Previous studies showed a potential role of DWI in 
predicting tumor response during and after CRT in locally 
advanced rectal cancer (LARC) patients. The purpose of 
this study was to determine whether changes in ADC 
values of LARC, obtained 2 weeks after the beginning of 
CRT, allow to predict response to treatment and whether 
they correlate with tumor histopathologic response. 
Material and Methods  
Forty-three patients affected by LARC were tr eated 
with CRT and received a 3.0T MRI with diffusion-weighted 
sequences before, 2 weeks during and 8 weeks after CRT. 
ADC values were calculated at each time point. The 
percentage of ADC changes at 2 weeks (ΔADC during) and 
after 8 weeks (ΔADC post) were then assessed. All data 
were correlated to histopathologic tumor regression 
grade (TRG), according to Mandard classification. The 
ADC values and ΔADCs of complete responders (CR=TRG1) 
and non-complete responders (non-CR=TRG 2-5) were 
compared. A receiver-operating characteristic curve 
(ROC) analysis was used to assess the diagnostic accuracy 
of ΔADC for differentiating CR from non-CR. The 
correlation with TRG was investigated using Spearman 
rank test. 
Results  
In 21 out of 43 (48.8%) patients no residual tumor cells 
were found after CRT and surgery (TRG1) and were 
considered complete responders. The remaining 22 
patients were classified as non-complete responders (4 
TRG2, 13 TRG3, 5 TRG4). Both ΔADC at 2 weeks (Figure 
1a) and post treatment (Figure 1b) were significantly 
higher in CR (33.9% and 57%, respectively) compared to 
non-CR (13.5% and 2.2%, respectively) group (p=0.006 and 
p<0.001, respectively). A significant moderate and good 
negative correlation was found between ΔADC during and 
ΔADC post and TRG (r=-0.418, p=0.007; r=-694, p≤0.001, 
respectively). In addition, ROC analysis revealed the 
following diagnostic performances: ΔADC at 2 weeks: AUC 
0.78 (0.08 standard error), p=0.004, cut-off 20.6% 
(sensitivity 75% and specificity 76.5%); ΔADC post 
treatment: AUC 0.94 (0.04 standard error), p≤0.001, cut-
off 22% (sensitivity 95% and specificity 82.4%). 
 
 
 
Conclusion  
ΔADC at 2 weeks after the beginning of CRT resulted a 
reliable tool to early assess treatment response, with an 
appreciable level of sensitivity and specificity. This can 
allow to perform surgery before or after 8 weeks interval-
to-CRT, according to MRI tumor response. 
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Purpose or Objective  
Clinical data on late toxicity and patient reported 
outcomes after intensity-modulated radiotherapy (IMRT) 
for neoadjuvant treatment of rectal cancer are severely 
lacking. Here, we report on a prospective study of high-
dose IMRT for locally advanced rectal cancer aiming to 
examine late toxicity and patient-reported outcomes 
(PROs). 
Material and Methods  
Patients with locally advanced (T3-4N0-2M0) rectal 
cancer were prospectively enrolled in this single-
institution study. They were treated with IMRT to 50Gy in 
30 fractions to elective pelvic lymph nodes with a 
simultaneous integrated boost (60Gy) to the primary 
tumour. Plans were optimized for target coverage, while 
sparing organs at risk. 5Gy brachytherapy or 6Gy external 
beam was delivered as further sequential tumour boost. 
Concomitant chemotherapy (UFT or capecitabine) was 
given on treatment days. TME surgery was scheduled 8 
weeks after end of radiotherapy. Clinical outcomes and 
toxicity (CTCAE v4.0) and PRO (EORTC QLQ CR29) were 
recorded at baseline, during treatment, and at 3, 6, 9, 
12, 16, 20, 24, 30 and 36 months follow-up. Overall 
survival (OS) and progression-free survival (PFS) were 
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evaluated using Kaplan-Meier estimates; toxicity and 
PROs were compared to baseline using paired Wilcoxon 
tests. 
Results  
Fifty-five patients (35 men / 20 women) were included; 
majority cT3 disease (42 patients) with cN+ (49 patients). 
Fifty-four patients received full external beam 
radiotherapy; median PTV for tumour and elective lymph 
nodes were 214cm3 and 1457cm3, respectively. Acute 
clinician scored side effects were mild, with only nine 
patients experiencing grade ≥2 bowel toxicity. Overall 
PRO scores were significantly worse at end of treatment 
compared to baseline (median 22.22 vs 13.89, p<0.0001). 
Surgery was conducted as planned in 51 patients. 
Thirteen patients (24%) had complete response of primary 
tumour to treatment (11 with pathological complete 
regression, two declined surgery after clinical complete 
response). All patients were followed for at least 2 years 
(median clinical follow-up 3.3 years, survival 4.8 years), 
excepting patients with disease progression (n=10 at 2 
years) or withdrawing consent for further study 
participation (n=9). OS and PFS at 3 years were 92.7% 
(95% CI 86.1-99.9%) and 68.4% (95% CI 56.7-82.6%), 
respectively. 64% of patients had a stoma at 2 years. 
Figure 1 shows clinician-scored toxicities (n=35) and 
patient-reported symptoms (n=30) at 2-year follow-up. 
Clinician-scored urinary urgency (p=0.01) and frequency 
(p<0.001) as well as patient-reported incontinence for 
gas (p=0.001) were significantly increased from baseline. 
Generally, patients reported more symptoms than 
clinicians across most symptom domains. However, 
overall PRO scores at late follow-up were lower (i.e. 
better) than at baseline, see Figure 2. 
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Conclusion  
Late outcomes of high dose IMRT for locally advanced 
rectal cancer appear promising, with low levels of 
toxicity. However, we observe under-reporting of 
toxicities by clinicians compared to PRO data. 
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Purpose or Objective  
Aim of this study was to extract a massive number of 
morphological(MP) and filtered Radiomic Features(RF) 
from pre-treatment T2 MRI in Locally Advanced Rectal 
Cancer (LARC) patients (pts) and select features able to 
predict pathological Complete Response (pCR). 
Material and Methods  
LARC pts were retrospectively enrolled from May 2008 to 
December 2014.   
All pts underwent neoadijuvant chemotherapy(nCRT) 
followed by surgery: Tumor Regression Grade(TRG) was 
assessed on pathological specimens, considering TRG1 as 
pCR. 
A pelvic MRI was performed in all pts before nCRT: Gross 
Tumor Volume(GTV) was delineated by 1 radiologist and 1 
radiation oncologist on T2 staging images in each case.  
61 RF(First-Order (FO), MP, and texture) were extracted 
using in-house Moddicom software.   
FO and textural features were calculated after filtering 
by Laplacian of Gaussian(LoG) using different settings(σ 
parameter range from 0,3 to 2,5 with a step of 0,01). 
12,763 RF were extracted for each pt and were divided 
into two groups: “LoG-Textural” and “Non-Textural”(MO 
and LoG-FO features).   
A Feature Selection(FS) for each separate group was 
performed(figure 1) using 10-fold Cross Validation(CV). 
For each folder a univariate correlation between outcome 
and each covariate at specific σ was evaluated using a 
Mann-Whitney(MN) test. We selected the statistically 
significant covariates (p-value < 0.05). If a feature was 
selected at different σ values, we chose the σ with the 
lowest p-value. A Logistic Regression Model(LRM) was 
applied on the resulting subset of features. The Area 
Under the ROC Curve(AUC) was evaluated and the group 
with the highest average value was selected.   
From this group, the final predictors were determined 
using the same strategy(figure 1) but in leave-one-
patient-out CV. The RF with an occurrence higher than 
90% were selected. 
Finally clinical features(cT and cN) were added and a LRM 
was applied on the external validation set(VS), computing 
the AUC value and the Hosmer-Lemeshow(HL) test. 
 
 
 
 
Results  
173 pts were selected in the Training Set(TS); 25 pts in 
the VS. No significant differences were observed in the 
distribution of clinical and pCR characteristics.  
The overall pCR was similar between TS and VS(27% vs 
28%). Using the PI and LoG filter, “Non-Textural” 
features were selected as the best predictors of pCR. The 
“Non-Textural” and “LoG-Textural” AUC values were 0,63 
and 0,61 respectively.   
Among all the final FR, the features with an occurrence 
>90% were 3: surface, volume, skewness (σ = 0,42). RF 
were finally combined with cT and cN. The final model 
consisted of cT(p<0,01), cN(p=0.72), surface (p=0,01), 
volume(p<0.01) and skewness(σ = 0,42) (p<0,01). The 
performance of the LRM was evaluated on external VS 
with an AUC of 81%(figure 2) and an HL of 0.85. 
 
 
 
Conclusion  
The model offered a promising performance with these 
settings. 
The exclusion of textural RF might depend on the 
application of LoG filter. Further investigations on 
different filtering and a suitable normalization algorithm 
are ongoing. 
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Purpose or Objective  
Treatment of locally advanced rectal cancer involves 
chemoradiation, followed by total mesorectum excision 
(TME). Complete response after chemoradiation is an 
accurate surrogate for long-term local control. However, 
